What question did this study set out to answer?

To assess the safety, tolerability, pharmacokinetics, and exploratory weight-loss efficacy of Y14, an extended-release peptide YY analogue, in overweight and obese individuals.

February 19, 2021Diabetes Obesity and MetabolismOpen Access

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

View Full Paper

Ask AI

Bookmark

Authors

TTTricia TanImperial College Healthcare NHS Trust JMJames MinnionShort and Associates (United States)BKBernard KhooUniversity College Hospital

Discussion

Member takes

Implication

Randomized placebo-controlled trial demonstrates significant weight loss and reduced appetite with peptide YY analogue Y14 in obese adults, supporting its development as a weekly obesity therapy.

Key Points

To assess the safety, tolerability, pharmacokinetics, and exploratory weight-loss efficacy of Y14, an extended-release peptide YY analogue, in overweight and obese individuals.
Conducted a Phase 1 randomized, placebo-controlled trial in a UK clinical trial unit consisting of a blinded single-ascending-dose stage (Part A, up to 36 mg; N=53) and a double-blind multiple-ascending-dose stage (Part B, 9–36 mg every 7–14 days for 28 days, up to five doses; N=24).
Evaluated safety and tolerability as the primary endpoint, pharmacokinetics as the secondary endpoint, and food intake, body weight, and glucose tolerance as exploratory endpoints.
Participants receiving multiple doses of Y14 achieved a significant weight loss of -2.87 to -3.58 kg compared with placebo at day 31 (P < 0.0001).
Food intake decreased substantially by 38% to 55% compared with placebo (P < 0.0001) without evidence of tachyphylaxis.
Pharmacokinetic data supported 7- to 14-day dosing intervals; adverse events were mostly mild and transient nausea, vomiting, or injection-site reactions, with no serious adverse events reported.

Cite This Study

Tan et al. (2021) studied this question.

synapsesocial.com/papers/6a7e4c26b44705ee4685681d https://doi.org/10.1111/dom.14358

View Full Paper

Ask AI

Bookmark

Implication

Randomized placebo-controlled trial demonstrates significant weight loss and reduced appetite with peptide YY analogue Y14 in obese adults, supporting its development as a weekly obesity therapy.

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider